ENG/中
老虎證券
行情
产品介绍
Cash Boost账户
新加坡股
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務
美國抗疫概念
1,401.15
-35.1008
-2.44%
漲家數:
3
跌家數:
15
平家數:
1
市盈率:
- -
高:
1,435.62
開:
1,435.62
低:
1,396.99
收:
1,436.25
資料載入中...
總覽
新聞
Biontech Se7月31日成交額為9326.64萬美元
市场透视
·
1小時前
特朗普致信全球17家制藥巨頭,敦促它們大幅削減美國藥品價格
格隆汇
·
3小時前
特朗普向藥企“開刀” 要求60天內降低美國藥價
智通财经
·
4小時前
Corvus Pharmaceuticals, Inc.盤中異動 快速下挫5.02%
市场透视
·
6小時前
莫德納盤中異動 早盤快速下跌5.04%報30.53美元
市场透视
·
昨天
美股異動|Moderna跌超3.2% 計劃今年年底前在全球裁員約10%
格隆汇
·
昨天
阿斯利康盤中異動 早盤股價大跌3.00%報74.30美元
市场透视
·
昨天
共生完成第1000批支持阿斯利康新冠疫苗的注射藥物產品Symbiosis Completes 1,000th Batch of Injectable Drug Products Supporting AstraZeneca COVID-19 Vaccine
动脉网
·
昨天
莫德納 計劃裁員 10%以削減成本
路透中文
·
昨天
華蓋資本許小林:中國醫藥產業併購時代來臨,四大趨勢引關注
21世纪经济报道
·
昨天
國內審評審批體系不斷優化,2025年創新藥上市數將創新高
制药网
·
昨天
細胞療法不香了?跨國製藥頭部宣佈三項合作管線終止!
制药网
·
昨天
大型藥企聚焦千億神經藥物市場,高額併購不斷
制药网
·
昨天
雅培7月30日成交額為6.89億美元
市场透视
·
昨天
Ocugen, Inc.盤中異動 快速拉昇6.80%
市场透视
·
昨天
Equillium, Inc.盤中異動 早盤股價大漲5.26%報0.420美元
市场透视
·
07-30
取代 EQC,梅賽德斯-奔馳發佈純電 SUV 新車 GLC EQ 預告
市场资讯
·
07-30
阿斯利康放棄3款細胞療法
谈思生物
·
07-30
輝瑞7月29日成交額為9.32億美元
市场透视
·
07-30
莫德納7月29日成交額為2.70億美元
市场透视
·
07-30
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4568/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"美國抗疫概念","latestPrice":1401.1527,"timestamp":1753991999999,"preClose":1436.2535,"halted":0,"volume":123793852,"delay":0,"changeRate":-0.024439,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":-35.10083,"latestTime":"07-31 16:00:00 EDT","open":1435.619,"high":1435.619,"low":1396.985,"amount":6407862381.340923,"amplitude":0.026899,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1754035200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.774153,"peRate":21.9369,"turnoverRate":0.008086,"increases":3,"decrements":15,"flats":1,"marketCap":1155022473418.25,"floatMarketCap":1134692282698.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1435.619,"amplitude":0.026899,"preClose":1436.2535,"low":1396.985,"pbRate":"3.774153","latestPrice":1401.1527,"volume":123793852,"delay":0,"open":1435.619,"prevYearClose":1274.8187,"prevWeekClose":1430.7134,"prevMonthClose":1377.5769,"prevQuarterClose":1377.5769,"fiveDayClose":1435.3163,"twentyDayClose":1397.328,"sixtyDayClose":1366.6433,"secType":"PLATE","market":"US","turnoverRate":0.008086,"peRate":21.9369,"marketCap":1155022473418.25,"floatMarketCap":1134692282698.75,"timestamp":1753991999999,"nameCN":"美國抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":3,"down":15,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2556868868","title":"Biontech Se7月31日成交額為9326.64萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2556868868","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556868868?lang=zh_tw&edition=fundamental","pubTime":"2025-08-01 09:25","pubTimestamp":1754011521,"startTime":"0","endTime":"0","summary":"美东时间2025年7月31日,Biontech Se成交额为9326.64万美元,成交额较昨日增加27.10%,当日成交量为85.91万股。Biontech Se于2025年7月31日跌2.32%,报107.5美元,该股过去5个交易日跌6.17%,年初至今跌5.66%,过去60日涨6.33%。BioNTech与几家大型制药公司合作,包括罗氏、礼来、辉瑞、赛诺菲和Genmab。冠状病毒疫苗是其首个商业化产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801092529a6cca0f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801092529a6cca0f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4535","BNTX","BK4551","BK4548","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2556854123","title":"特朗普致信全球17家制藥巨頭,敦促它們大幅削減美國藥品價格","url":"https://stock-news.laohu8.com/highlight/detail?id=2556854123","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556854123?lang=zh_tw&edition=fundamental","pubTime":"2025-08-01 07:53","pubTimestamp":1754006008,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0238689110.USD","LU0225284248.USD","NVO","LU1894683348.USD","LU0203202063.USD","SG9999015978.USD","LU2750360641.GBP","BK1191","IE00BLSP4239.USD","IE0004445239.USD","LU0689472784.USD","LU1989771016.USD","LU0094547139.USD","BK4550","LU1868837300.USD","SG9999013999.USD","SGXZ81514606.USD","01477","BK4007","LU0823434740.USD","LU0225771236.USD","LU0385154629.USD","LU1868836914.USD","SG9999003800.SGD","IE0009355771.USD","LU0471298777.SGD","LU2211815571.USD","PFE","LU1551013342.USD","LU2552382058.USD","LU0256863811.USD","BK4588","LLY","LU2552382132.HKD","IE00BJJMRZ35.SGD","SG9999015986.USD","LU0154236417.USD","LU0354030511.USD","SGXZ31699556.SGD","LU1127390331.HKD","SG9999002224.SGD","LU0456855351.SGD","LU1712237335.SGD","159891","BK4568","IE000M9KFDE8.USD","LU0198837287.USD","LU0256863902.USD","LU1720051017.SGD","LU2750360997.AUD"],"gpt_icon":0},{"id":"2556851508","title":"特朗普向藥企“開刀” 要求60天內降低美國藥價","url":"https://stock-news.laohu8.com/highlight/detail?id=2556851508","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556851508?lang=zh_tw&edition=fundamental","pubTime":"2025-08-01 06:00","pubTimestamp":1753999200,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,美国总统特朗普周四表示,他已致信包括辉瑞、诺和诺德、强生在内的17家大型制药公司,要求其在未来60天内采取具体行动,降低美国药品价格,否则将动用“一切可用手段”保护美国家庭免受“药价暴利”的影响。该政策主张将美国部分药品价格与海外价格挂钩,以压低国内药价。辉瑞称与特朗普政府和国会的讨论“富有成效”,诺华则表示正在审阅信件内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1324521.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4568","LU0321505439.SGD","BK4599","LU1066051498.USD","LU1093756325.SGD","BK4550","BK4585","IE00B19Z3B42.SGD","LU0154236417.USD","LU1057294990.SGD","LU0058720904.USD","SG9999002232.USD","LU1894683348.USD","IE00BLSP4239.USD","LU1883839398.USD","SG9999013999.USD","NVO","BK4534","LU0234572021.USD","IE00B19Z3581.USD","BK4532","LU1093756168.USD","PFE","IE000M9KFDE8.USD","LU0306806265.USD","IE00BKVL7J92.USD","LU1894683264.USD","LU0456855351.SGD","LU1066053197.SGD","IE00BZ1G4Q59.USD","LU0868494617.USD","IE00BLSP4452.SGD","LU0122379950.USD","SG9999002224.SGD","BK4581","BK4533","LU0225284248.USD","SG9999001176.USD","SG9999003800.SGD","LU0321505868.SGD","BK4007","LU0170899867.USD","LU0225771236.USD","BK4592","LU0289739699.SGD","LU1023059063.AUD","SG9999001176.SGD","LU0306807586.USD","SG9999011175.SGD","LU0985481810.HKD"],"gpt_icon":1},{"id":"2556900853","title":"Corvus Pharmaceuticals, Inc.盤中異動 快速下挫5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556900853","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556900853?lang=zh_tw&edition=fundamental","pubTime":"2025-08-01 03:59","pubTimestamp":1753991979,"startTime":"0","endTime":"0","summary":"北京时间2025年08月01日03时59分,Corvus Pharmaceuticals, Inc.股票出现异动,股价急速跳水5.02%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中,整体涨幅为1.39%。Corvus Pharmaceuticals, Inc.公司简介:Corvus Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司,致力于开发精准靶向对免疫细胞成熟和功能至关重要的蛋白质的候选产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801035940972af822&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801035940972af822&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","CRVS","BK4139"],"gpt_icon":0},{"id":"2556837567","title":"莫德納盤中異動 早盤快速下跌5.04%報30.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2556837567","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556837567?lang=zh_tw&edition=fundamental","pubTime":"2025-07-31 23:24","pubTimestamp":1753975440,"startTime":"0","endTime":"0","summary":"北京时间2025年07月31日23时24分,莫德纳股票出现异动,股价急速下挫5.04%。截至发稿,该股报30.53美元/股,成交量409.878万股,换手率1.06%,振幅4.01%。莫德纳股票所在的生物技术行业中,整体涨幅为2.64%。莫德纳公司简介:莫德纳是一家商业阶段的生物技术公司,成立于 2010 年,并于 2018 年 12 月进行首次公开募股。该公司的 mRNA 技术通过其 COVID-19 疫苗迅速得到验证,该疫苗于 2020 年 12 月在美国获得批准。截至 2024年9月,莫德纳拥有处于临床试验中的40个mRNA开发候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073123240094c69bba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073123240094c69bba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4533","BK4532","BK4568","MRNA","BK4548","BK4585","BK4588","BK4534","BK4139","BK4501","BK4551"],"gpt_icon":0},{"id":"2555083912","title":"美股異動|Moderna跌超3.2% 計劃今年年底前在全球裁員約10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555083912","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555083912?lang=zh_tw&edition=fundamental","pubTime":"2025-07-31 22:11","pubTimestamp":1753971105,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4533","159646","BK4534","BK4568","BK4588","BK4551","BK4139","BK4585","MRNA","BK4548","BK4532","BK4501"],"gpt_icon":0},{"id":"2555839741","title":"阿斯利康盤中異動 早盤股價大跌3.00%報74.30美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555839741","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555839741?lang=zh_tw&edition=fundamental","pubTime":"2025-07-31 21:31","pubTimestamp":1753968698,"startTime":"0","endTime":"0","summary":"北京时间2025年07月31日21时31分,阿斯利康股票出现波动,股价急速下跌3.00%。截至发稿,该股报74.30美元/股,成交量70.4185万股,换手率0.02%,振幅0.46%。阿斯利康股票所在的制药行业中,整体跌幅为0.96%。该信息摘要如下:二季度阿斯利康核心每股收益达2.17美元,同比增长10%,略超市场预期。据阿斯利康周二发布的业绩显示,二季度公司收入达到144.6亿美元,同比增长12%,超过分析师预期的141.5亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731213138972a4bdd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731213138972a4bdd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LU2236285917.USD","BK4568","LU2462157665.USD","BK4585","AZN","BK4588","LU0109394709.USD","LU1829250122.USD","LU2417539215.USD","LU2456880835.USD","LU0889565916.HKD","BK4007"],"gpt_icon":0},{"id":"2555354748","title":"共生完成第1000批支持阿斯利康新冠疫苗的注射藥物產品Symbiosis Completes 1,000th Batch of Injectable Drug Products Supporting AstraZeneca COVID-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2555354748","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555354748?lang=zh_tw&edition=fundamental","pubTime":"2025-07-31 21:05","pubTimestamp":1753967100,"startTime":"0","endTime":"0","summary":"This achievement underscores Symbiosis’s role in supporting critical medical advancements. The completion of 1,000 batches highlights the company’s capacity for large-scale production and its involvement in high-profile projects such as the AstraZeneca vaccine. Symbiosis continues to play a key part in addressing public health challenges through its expertise in injectable drug manufacturing..这一成就突显了共生公司在支持关键医疗进步方面的作用。完成1000批次的生产彰显了该公司的大规模生产能力,以及其参与阿斯利康疫苗等高知名度项目的能力。共生公司通过其在注射药物制造方面的专业知识,继续在应对公共卫生挑战中发挥重要作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073121071694c652c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073121071694c652c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1829250122.USD","BK4548","BK4568","LU2417539215.USD","LU0889565916.HKD","LU0109394709.USD","BK4535","LU2456880835.USD","LU2462157665.USD","BK4139","AZN","BK4585","LU2236285917.USD","BK4588","BK4551","BK4007","LU0320765992.SGD","BNTX"],"gpt_icon":0},{"id":"2555757882","title":"莫德納 計劃裁員 10%以削減成本","url":"https://stock-news.laohu8.com/highlight/detail?id=2555757882","media":"路透中文","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555757882?lang=zh_tw&edition=fundamental","pubTime":"2025-07-31 19:26","pubTimestamp":1753961211,"startTime":"0","endTime":"0","summary":"莫德纳 计划裁员 10%以削减成本路透7月31日 - 莫德纳 MRNA.O公司周四表示,在其COVID-19疫苗销售放缓之际,该公司计划在今年年底前裁减约10%的全球员工,以削减成本。\"莫德纳公司首席执行官Stephane Bancel在给员工的一份备忘录中说:\"到今年年底,我们的员工人数预计将少于5000人。(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nL4T3TS1C2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4588","BK4534","BK4533","BK4139","BK4532","BK4548","MRNA","BK4501","BK4585","BK4568"],"gpt_icon":0},{"id":"2555002328","title":"華蓋資本許小林:中國醫藥產業併購時代來臨,四大趨勢引關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2555002328","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555002328?lang=zh_tw&edition=fundamental","pubTime":"2025-07-31 15:34","pubTimestamp":1753947247,"startTime":"0","endTime":"0","summary":"华盖资本创始合伙人董事长许小林以“中国医药产业并购时代来临”为主题,谈到中美医药产业的并购发展情况,中国医药产业并购时代来临的主要动因,以及中国医药行业并购的四大趋势。中国医药产业迎来并购时代,四大趋势值得关注回到中国市场来看,2015年前后曾经有过并购热潮,但当时的许多并购并不是真正基于企业自身需求,带来的“后遗症”也很多。展望未来,许小林认为,中国医药产业并购存在四大趋势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731153723a6cb17e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731153723a6cb17e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0289961442.SGD","DHR","LU1061106388.HKD","SG9999003800.SGD","BK4550","IE00BLSP4239.USD","LU0187121727.USD","LU0390134368.USD","LU1057294990.SGD","BK4534","LU2023250504.SGD","LU2106854487.HKD","LU1551013342.USD","LU0289960550.SGD","LU1894683264.USD","LU0820561909.HKD","LU0511384066.AUD","LU0097036916.USD","LU0306807586.USD","SG9999013999.USD","LU0058720904.USD","BK4588","IE00BZ1G4Q59.USD","SG9999002232.USD","IE000M9KFDE8.USD","BK4599","BK4007","BK4121","LU0225771236.USD","LU2355687059.USD","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU0820562030.AUD","SG9999004303.SGD","LU2244417387.USD","LU1023059063.AUD","BK4592","BK4585","LU0170899867.USD","LU1066051498.USD","LU1804176565.USD","LU2125909593.SGD","PFE","LU0882574055.USD","BK4568","LU2211814178.USD","SG9999001176.USD","LU0321505868.SGD","SG9999002224.SGD","LU1066053197.SGD"],"gpt_icon":0},{"id":"2555001921","title":"國內審評審批體系不斷優化,2025年創新藥上市數將創新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2555001921","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555001921?lang=zh_tw&edition=fundamental","pubTime":"2025-07-31 14:54","pubTimestamp":1753944861,"startTime":"0","endTime":"0","summary":"越来越多国内外,创新药开始在中国获批上市。据统计,今年上半年,我国创新药物审批领域共有43个创新药获得上市批准。目前,F627已在全球34个国家获准注册上市,是国内为数不多的同时在中美欧获批的全球创新药。业内分析认为,创新药的快速上市,得益于审评审批体系的不断优化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073114552094c588bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073114552094c588bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1914381329.SGD","IE00BGHQF631.EUR","BK4533","IE00BDGV0183.EUR","IE00BLSP4239.USD","LU1929549753.HKD","LU0203347892.USD","LU1935042991.SGD","IE00BFTCPJ56.SGD","LU1280957306.USD","LU2602419157.SGD","IE00BVYPNV92.GBP","LU2505996681.GBP","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0058720904.USD","BK4588","JNJ","SG9999002232.USD","IE0002141913.USD","LU0114720955.EUR","IE000M9KFDE8.USD","LU2430703251.USD","IE00BLSP4452.SGD","LU1267930813.SGD","LU0098860793.USD","LU0795875086.SGD","IE00B19Z3B42.SGD","LU1221951046.USD","IE00BBT3K403.USD","LU2430703095.HKD","IE0009355771.USD","LU0640476718.USD","LU0795875169.SGD","LU1032466523.USD","LU1023059063.AUD","BK4592","LU2468319806.SGD","LU0203345920.USD","BK4585","LU1066051498.USD","LU1221951129.SGD","LU1032955483.USD","LU0882574055.USD","BK4568","BK4532","LU0320765646.SGD","SG9999002224.SGD","IE00B7SZLL34.SGD","LU0345770308.USD"],"gpt_icon":0},{"id":"2555005366","title":"細胞療法不香了?跨國製藥頭部宣佈三項合作管線終止!","url":"https://stock-news.laohu8.com/highlight/detail?id=2555005366","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555005366?lang=zh_tw&edition=fundamental","pubTime":"2025-07-31 13:57","pubTimestamp":1753941423,"startTime":"0","endTime":"0","summary":"近日,阿斯利康宣布终止三项细胞疗法合作管线,分别是通过收购得到的TCR-T疗法NT-125,以及两款CAR-T疗法AZD5851和AZD6422。无独有偶,专注于TCR-T细胞疗法的Biotech公司Adaptimmune近日也宣布将一系列TCR-T疗法打包出售,这一举措导致公司股价以71%的断崖式暴跌震惊市场。这表明,阿斯利康等大药企并非放弃细胞疗法,而是在进行战略调整,淘汰那些前景不够明朗或与公司整体发展战略不符的项目,将资源集中到更具竞争力和发展潜力的管线中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073113572094c56f5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073113572094c56f5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","LU0889565916.HKD","LU2462157665.USD","LU2417539215.USD","ORR","BK4585","LU1829250122.USD","LU0320765992.SGD","BK4007","LU2456880835.USD","LU0109394709.USD","AZN","BK4588","LU2236285917.USD"],"gpt_icon":0},{"id":"2555239077","title":"大型藥企聚焦千億神經藥物市場,高額併購不斷","url":"https://stock-news.laohu8.com/highlight/detail?id=2555239077","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555239077?lang=zh_tw&edition=fundamental","pubTime":"2025-07-31 12:00","pubTimestamp":1753934458,"startTime":"0","endTime":"0","summary":"庞大的市场规模,使精神类药物市场开始成为全球药企新的竞争焦点,同时也带起了该赛道的风口。据悉,Gilgamesh专注于开发用于治疗抑郁症、焦虑症、药物成瘾及其他精神疾病的疗法。2024年8月1日,艾伯维发布公告,其将以87亿美元完成对神经科学生物技术公司Cerevel Therapeutics的收购。除了艾伯维,近年来还有不少大型药企也正在通过高额并购与合作抢占神经药物领域赛道制高点。据了解,阿斯利康在神经科学领域的撤离并非突然之举。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073112014897292f84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073112014897292f84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BFXG1179.USD","LU0345769128.USD","BK4592","IE00BVYPNW00.USD","LU1244550494.USD","LU2129689514.USD","IE0034235303.USD","IE00B2B36J28.USD","BK4559","LU1023059063.AUD","LU2505996509.AUD","BK4568","IE00B7SZLL34.SGD","LU0234572021.USD","LU1074936037.SGD","BK4533","LU0795875086.SGD","LU1261432733.SGD","LU2592432038.USD","LU1674673428.USD","LU1032955483.USD","LU0345770308.USD","LU2505996681.GBP","LU1244550577.SGD","LU0098860793.USD","CNS","BK4007","LU1894683264.USD","PFE","IE00B19Z3581.USD","LU2430703251.USD","LU0912757837.SGD","LU1162221912.USD","IE0009355771.USD","IE00BGHQF631.EUR","BK4504","LU1935042991.SGD","LU0466842654.USD","LU1032466523.USD","AZN","LU0345770993.USD","LU1196500208.SGD","LU2430703178.SGD","IE00B42XCP33.USD","LU0985320562.USD","LU1280957306.USD","BK4135","LU1929549753.HKD","IE00BSNM7G36.USD","JNJ","LU0203347892.USD","LU0792757196.USD"],"gpt_icon":0},{"id":"2555763220","title":"雅培7月30日成交額為6.89億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555763220","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555763220?lang=zh_tw&edition=fundamental","pubTime":"2025-07-31 09:15","pubTimestamp":1753924522,"startTime":"0","endTime":"0","summary":"美东时间2025年7月30日,雅培成交额为6.89亿美元,成交额较昨日减少7.21%,当日成交量为535.97万股。雅培于2025年7月30日涨0.42%,报128.55美元,该股过去5个交易日涨2.16%,年初至今涨15.29%,过去60日跌2.78%。雅培约 60% 的销售额来自美国以外地区。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731091538a6ca7dd3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731091538a6ca7dd3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1061106388.HKD","LU1914381329.SGD","SGXZ23171101.USD","LU1721429402.USD","BK4533","LU2237957811.SGD","LU0266013472.USD","BK4566","LU1057294990.SGD","LU1989763690.USD","IE00BFTCPJ56.SGD","LU2089984988.USD","LU1989763427.SGD","BK4581","LU0234572021.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU2133065610.SGD","LU0868494617.USD","BK4588","SG9999002232.USD","BK4504","IE00B4R5TH58.HKD","BK4082","IE0002141913.USD","LU1721429741.USD","IE00BJJMRZ35.SGD","SG9999004303.SGD","ABT","LU2112291526.USD","IE0009355771.USD","LU1023059063.AUD","BK4592","LU2468319806.SGD","BK4585","LU0170899867.USD","LU1691799644.USD","BK4568","LU2237957902.USD","SG9999002224.SGD","LU2211815571.USD","LU0122379950.USD"],"gpt_icon":0},{"id":"2555025683","title":"Ocugen, Inc.盤中異動 快速拉昇6.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555025683","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555025683?lang=zh_tw&edition=fundamental","pubTime":"2025-07-31 00:34","pubTimestamp":1753893284,"startTime":"0","endTime":"0","summary":"北京时间2025年07月31日00时34分,Ocugen, Inc.股票出现波动,股价快速上涨6.80%。Ocugen, Inc.股票所在的生物技术行业中,整体涨幅为0.73%。其相关个股中,Replimune Group, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Osr Holdings Inc C/Wts 09/02/2028 涨幅较大,Tnf Pharmaceuticals, Inc.、Salarius Pharmaceuticals, Inc.、Replimune Group, Inc.较为活跃,换手率分别为401.58%、213.16%、187.48%,振幅较大的相关个股有Replimune Group, Inc.、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ,振幅分别为55.33%、53.86%、47.44%。Ocugen, Inc.公司简介:Ocugen Inc 公司专注于发现、开发和商业化新型基因和细胞疗法和疫苗,以改善健康并为全球患者带来希望。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731003444a46beb5b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731003444a46beb5b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OCGN","BK4568","BK4563","BK4139"],"gpt_icon":0},{"id":"2555704724","title":"Equillium, Inc.盤中異動 早盤股價大漲5.26%報0.420美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555704724","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555704724?lang=zh_tw&edition=fundamental","pubTime":"2025-07-30 21:53","pubTimestamp":1753883622,"startTime":"0","endTime":"0","summary":"北京时间2025年07月30日21时53分,Equillium, Inc.股票出现异动,股价急速拉升5.26%。截至发稿,该股报0.420美元/股,成交量3.1605万股,换手率0.09%,振幅5.76%。Equillium, Inc.股票所在的生物技术行业中,整体涨幅为0.40%。Equillium, Inc.公司简介:Equillium Inc是一家临床阶段的生物技术公司,致力于开发新的治疗方法,以治疗严重的自身免疫性和炎症性疾病,或免疫炎症性疾病,具有高度未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730215342a6c9dc98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730215342a6c9dc98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EQ","BK4568"],"gpt_icon":0},{"id":"2555044891","title":"取代 EQC,梅賽德斯-奔馳發佈純電 SUV 新車 GLC EQ 預告","url":"https://stock-news.laohu8.com/highlight/detail?id=2555044891","media":"市场资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555044891?lang=zh_tw&edition=fundamental","pubTime":"2025-07-30 20:18","pubTimestamp":1753877880,"startTime":"0","endTime":"0","summary":"IT之家 7 月 30 日消息,据外媒 Carscoops 今晚报道,梅赛德斯-奔驰全新打造的纯电动 GLC 车型即将正式亮相,新车将登陆 9 月的 IAA Mobility 展会。GLC EV 预计将延续燃油版 GLC 的整体体型,并在外观设计上焕然一新。据悉,首发版本为 GLC 400 4Matic EQ Technology。除了电动 GLC ,奔驰还将在慕尼黑展示 MB.Drive Assist Pro 半自动驾驶系统,并提供搭载该系统的 CLA 车型试乘体验。此外,极具视觉冲击力的 Concept AMG GT XX 概念车也将与 GLC EV 一同登场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2025-07-30/doc-infihfyq8199761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EQC","EQ","BK4139","BK4568","BK4194","BK4223"],"gpt_icon":0},{"id":"2555137660","title":"阿斯利康放棄3款細胞療法","url":"https://stock-news.laohu8.com/highlight/detail?id=2555137660","media":"谈思生物","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555137660?lang=zh_tw&edition=fundamental","pubTime":"2025-07-30 15:20","pubTimestamp":1753860023,"startTime":"0","endTime":"0","summary":"2025.07.30本文字数:1075,阅读时长大约2.7分钟导读:7月29日财报出炉:阿斯利康连砍3条细胞疗法管线,却10亿美元押注新平台,细胞疗法版图重构。7月29日,阿斯利康在二季度财报里宣布,对旗下多条细胞疗法管线进行战略梳理,砍掉或按下暂停键若干项目,以聚焦资源。尽管这三条管线被砍,阿斯利康并未缩减细胞疗法版图,反而继续加码。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730153257a6c9375f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730153257a6c9375f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LU0889565916.HKD","LU2236285917.USD","LU0109394709.USD","LU2417539215.USD","LU2456880835.USD","BK4007","BK4568","LU1829250122.USD","BK4588","AZN","LU0320765992.SGD","LU2462157665.USD"],"gpt_icon":0},{"id":"2555094058","title":"輝瑞7月29日成交額為9.32億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555094058","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555094058?lang=zh_tw&edition=fundamental","pubTime":"2025-07-30 13:09","pubTimestamp":1753852181,"startTime":"0","endTime":"0","summary":"美东时间2025年7月29日,辉瑞成交额为9.32亿美元,成交额较昨日增加22.72%,当日成交量为3849.98万股。辉瑞于2025年7月29日跌0.04%,报24.3美元,该股过去5个交易日跌1.67%,年初至今跌3.47%,过去60日涨5.27%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-07-29|9.32亿|22.72%|3849.98万|#|2025-07-28|7.60亿|-13.99%|3109.66万|#|2025-07-25|8.83亿|35.68%|3564.34万|#|2025-07-24|6.51亿|-39.02%|2567.24万|#|2025-07-23|10.67亿|-10.89%|4207.33万|辉瑞是世界上最大的制药公司之一,年销售额约为600亿美元。辉瑞在全球销售这些产品,国际销售额占总销售额的40%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730130942a46adbde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730130942a46adbde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002270589.USD","LU1057294990.SGD","LU1894683264.USD","SG9999001176.SGD","SG9999011175.SGD","LU1894683348.USD","LU0170899867.USD","IE00B19Z3B42.SGD","LU0234572021.USD","LU0289739699.SGD","LU0306806265.USD","LU0122379950.USD","LU0321505868.SGD","LU1023059063.AUD","SG9999002224.SGD","BK4007","IE00BBT3K403.USD","BK4550","LU1066053197.SGD","SG9999002232.USD","IE000M9KFDE8.USD","SG9999001176.USD","BK4534","LU0868494617.USD","IE00B19Z3581.USD","LU0985481810.HKD","SGXZ57979304.SGD","LU0306807586.USD","BK4588","BK4568","LU0058720904.USD","LU0456855351.SGD","BK4533","BK4599","PFE","IE00BLSP4452.SGD","SG9999013999.USD","BK4592","LU0225771236.USD","BK4585","SG9999003800.SGD","LU1883839398.USD","BK4581","IE00BLSP4239.USD","LU0321505439.SGD","LU1066051498.USD","LU0225284248.USD"],"gpt_icon":1},{"id":"2555094540","title":"莫德納7月29日成交額為2.70億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555094540","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555094540?lang=zh_tw&edition=fundamental","pubTime":"2025-07-30 12:14","pubTimestamp":1753848865,"startTime":"0","endTime":"0","summary":"美东时间2025年7月29日,莫德纳成交额为2.70亿美元,成交额较昨日增加41.39%,当日成交量为829.55万股。莫德纳于2025年7月29日跌3.69%,报32.66美元,该股过去5个交易日跌0.21%,年初至今跌21.45%,过去60日涨20.83%。该公司的 mRNA 技术通过其 COVID-19 疫苗迅速得到验证,该疫苗于 2020 年 12 月在美国获得批准。截至 2024年9月,莫德纳拥有处于临床试验中的40个mRNA开发候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730121432a6c8f2ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730121432a6c8f2ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4568","BK4585","BK4534","BK4501","MRNA","BK4588","BK4551","BK4532","BK4533","BK4548"],"gpt_icon":1}],"pageSize":20,"totalPage":9,"pageCount":1,"totalSize":168,"code":"91000000","status":"200"}]}}